Column: M&A
Why the Big Shifts in Gene Therapy Investments? It’s Late in the Game
Nigel Walker
Nice Insight
PAO-03-022-NI-08Mar 23, 2022
Column: Clinical Trials
How Artificial Intelligence May Drive the Future of Clinical Trials
James Grote
Nice Insight
PAO-03-022-NI-01Mar 23, 2022
Column: Regulatory Spotlight
New FDA Guidance on Real World Evidence/Real World Data
David Alvaro, Ph.D.
Pharma's Almanac
PAO-03-022-NI-03Mar 23, 2022
Column: New Drug Watch
Alzheimer Drug Still Controversial
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-03-022-NI-04Mar 23, 2022
Column: Technology
mRNA Technology: Is the Long Path Behind Leading to Endless Successes Ahead?
Cynthia A. Challener, Ph.D.; David Alvaro, Ph.D.; Danielle Alvarez
Pharma's Almanac
PAO-03-022-NI-02Mar 23, 2022
Column: Investment
2021 Was a Great Year for Biotech IPOs, Depending on When You Got Out
Danielle Alvarez
Pharma's Almanac
PAO-03-022-NI-07Mar 23, 2022
Column: Regional
Expanding the Cell and Gene Therapy Ecosystem in Philadelphia
David Alvaro, Ph.D.
Pharma's Almanac
PAO-12-21-CL-05Mar 23, 2022
Recombinant Antibody Production
HEK Cells vs. CHO Cells in Recombinant Antibody Production: What's the Better Choice
evitria AG
PAO-03-022-CL-22Mar 22, 2022
Biotechs
10 Promising Biotechs Aiming to Transform Medicine
David Alvaro, Ph.D.; Danielle Alvarez
Pharma's Almanac
PA564Mar 22, 2022
Biomanufacturing
Unique Vector Expression Technologies for Boosting Protein Production in E. coli
Trond Erik Vee Aune, Ph.D.
Vectron Biosolutions
PAO-02-022-CL-16Mar 20, 2022
Cell Culture
Changing the Future of Cell Culture and Accelerating Next-Generation Therapies
A.J. Mellott, Ph.D.; Scott Leigh
Ronawk
PAO-02-022-CL-20Mar 20, 2022
Gene Therapy Analytics
Overcoming Analytical Challenges for Gene Therapies
Jennifer Chadwick, Ph.D.
ProtaGene
PAO-02-022-CL-14Mar 20, 2022
COVID-19 Vaccines
Will the Second Wave of COVID-19 Vaccines Have the Improved Properties Needed to End the Pandemic?
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-03-022-NI-05Mar 18, 2022
Process Validation
Streamlining Process Validation for Drug Substance Manufacturing
Gerhard Noessner, Ph.D.; Juergen Utz, Ph.D.; Juergen Bank, Ph.D.
Fareva
PAO-02-022-CL-19Mar 15, 2022
Investment
Global Investment Trends and Getting Noticed by PE/VC Firms
Iesan Tsai
Kiri Capital
PAO-02-022-CL-15Mar 15, 2022
Sterile
Sterile Injectables Device and Packaging Trends
James Grote
Nice Insight
PAO-02-022-NI-01Mar 14, 2022
Mesenchymal Stem Cells
The Exciting Growth Curve for hMSCs Must Be Facilitated by Manufacturing Advances
David Alvaro, Ph.D.
Pharma's Almanac
PAO-12-21-NI-01Mar 12, 2022
Solubility
The Limitless Potential of Thin Film Freezing
Glenn Mattes
TFF Pharmaceuticals, Inc.
PAO-01-22-CL-04Mar 12, 2022
Neurodegenerative Diseases
Pioneering Nanocatalysis to Revolutionize Treatments for Neurodegenerative Diseases
Rob Etherington
PAO-01-22-CL-06Mar 12, 2022
Mesenchymal Stem Cells
Moving Beyond the Industrialization of MSCs
Tim Kelly, Ph.D.
RoosterBio
PAO-12-21-CL-06Mar 12, 2022